454 related articles for article (PubMed ID: 27269043)
1. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
[TBL] [Abstract][Full Text] [Related]
2. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
3. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
[TBL] [Abstract][Full Text] [Related]
8. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Nedd M; Garland S; Falk N; Wilk A
Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
[TBL] [Abstract][Full Text] [Related]
10. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
[TBL] [Abstract][Full Text] [Related]
11. Ubrogepant for the treatment of migraine.
Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
[TBL] [Abstract][Full Text] [Related]
12. Ubrogepant to treat migraine.
Dhir A
Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy, tolerability, and safety of ubrogepant.
Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
15. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Goadsby PJ; Blumenfeld AM; Lipton RB; Dodick DW; Kalidas K; M Adams A; Jakate A; Liu C; Szegedi A; Trugman JM
Cephalalgia; 2021 Apr; 41(5):546-560. PubMed ID: 33241721
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
